Cavu Management, LP's Form 4 filing
Lantern Pharma Inc. (LTRN) · filed Dec 1, 2023
- Accession no.
- 0001104659-23-122539
- Filed
- Dec 1, 2023, 6:00 AM ET
- Trade date
- Nov 29, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $500.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cavu Management, LPCIK 0001813270 | 10% Owner |
| Cavu Advisors, LLCCIK 0001813310 | 10% Owner |
| BP Directors, LPCIK 0001813311 | 10% Owner |
| Kreis Leslie W.CIK 0001813316 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | Common Stock | SSaleDisposed | −53,640 | $3.44 | −$184,521.6 | 217,553 | Indirect | |
| Nov 29, 2023 | Common Stock | SSaleDisposed | −91,708 | $3.44 | −$315,475.52 | 371,950 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Aaron Glenn Louis Fletcher as the designated filer. Exhibit 24.1 - Power of Attorney